Broad Institute

AUGUST 24, 2022

The research team used an innovative analytic approach that they previously developed called microscaled proteogenomics to analyze tumor biopsies taken from TNBC patients prior to treatment with carboplatin and docetaxel combination chemotherapy.

DNA 52

DNA Protein Expression Treatment Protein Production 52

Molecule Blog

MARCH 17, 2023

For instance, RNA sequencing is highly sensitive to batch effects , and using a single high-quality RNAseq provider to federate data is more likely to result in the highest statistical power than multiple providers who don’t share data and correct each dataset for data science purposes.

Engineering 52

Engineering Research Clinical Trials Government 52

The Pharma Data

NOVEMBER 16, 2020

The study also included communities that have historically been under-represented in clinical research and have been disproportionately impacted by COVID-19. CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Nov. 16, 2020– Moderna, Inc. at large.

Vaccine 52

Vaccine Clinical Trials FDA Disease 52

Drug Target Review

AUGUST 22, 2023

This Q&A explores how pre-clinical research is being used to identify potential therapies for Huntington’s disease, a devastating condition that currently lacks disease- modifying treatments. However, this disease has proven a hard nut to crack.

Therapies 98

Therapies Disease Treatment RNA 98

Advarra

MARCH 31, 2023

Among the various regulatory bodies providing oversight on clinical research, only the institutional biosafety committee (IBC) has a purview specific to research involving engineered genetic materials. The post Risk Assessment for use of Engineered Genetic Materials in Clinical Research appeared first on Advarra.

Engineering 52

Engineering Clinical Research Research Virus 52

The Pharma Data

MARCH 9, 2021

Lenacapavir is a potential first-in-class capsid inhibitor that is designed to inhibit HIV replication as it interferes with the disassembly of the HIV capsid core, inhibits the role of capsid proteins during viral RNA/DNA translocation to the nucleus, and disrupts assembly of the capsid core.

Treatment 52

Treatment RNA Trials Science 52

The Pharma Data

AUGUST 31, 2021

Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a 6-monthly maintenance dose ‡ , in the community setting. comments Jules Payne, Chief Executive at HEART UK, the cholesterol charity. About inclisiran.

Therapies 52

Therapies Disease RNA Clinical Trials 52

The Pharma Data

JULY 29, 2021

At week 24, results showed that bulevirtide alone or in combination with peginterferon alfa-2a, is associated with a significant HDV RNA decline and improvements in biochemical disease activity. Gilead welcomed William Grossman, MD, PhD, as Senior Vice President, Oncology Clinical Research.

Science 52

Science Production Treatment FDA Approval 52

keypoint

SEPTEMBER 6, 2023

From mitochondrial pathology to pulmonary, neurological and metabolic impacts, the meeting integrated a wide range of research to identify disease drivers and causes of systemic and inexplicable symptoms. Get On Demand Access for the meeting!

Treatment 74

Treatment Disease Vaccine RNA 74

The Pharma Data

OCTOBER 27, 2020

As a class, DARPin® therapeutics have demonstrated over years of clinical research a number of characteristics that enhance their profile as antiviral therapeutics for a global pandemic. ” Collaboration Terms and Share Subscription.

Therapies 40

Therapies Virus Treatment Clinical Trials 40

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

Vaccine 52

Vaccine FDA Clinical Trials Disease 52

The Pharma Data

SEPTEMBER 1, 2021

Molnupiravir (MK-4482/EIDD-2801) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52

Conversations in Drug Development Trends

MAY 30, 2024

This approach is facilitated by developing ASOs and RNA interference (RNAi) therapies, which target the various molecular and genetic mechanisms contributing to ALS pathophysiology and disease progression. As we continue to explore current treatments and venture into new avenues of research, there lies hope for those affected by ALS.

Treatment 81

Treatment Clinical Trials Small Molecule Therapies 81

PPD

NOVEMBER 8, 2022

PPD, Thermo Fisher Scientific’s clinical research business, surveyed more than 150 biotech and biopharma leaders this year to assess trends in the drug development industry, yielding data we’ll cite throughout this blog. In addition, adaptive trial designs will contribute to innovations in clinical research insights.

Clinical Trials 52

Clinical Trials Trials Drug Development Clinical Research 52

PPD

MARCH 28, 2025

Oligonucleotides, also known as oligos, are strands of artificially created DNA or RNA that are instrumental in numerous molecular and synthetic biology applications. These applications range from genetic testing and forensic research to next-generation sequencing (NGS).

Laboratories 52

Laboratories Production International RNA 52

NIH Director's Blog: Drug Development

JANUARY 5, 2016

This gene-editing system consists of a short segment of RNA that is attached to an enzyme. The RNA is preprogrammed to find a distinct short sequence of DNA and deliver the enzyme, which acts like a scalpel to slice the sequence out of the genome. It’s fast and pretty precise.

Vaccine 52

Vaccine Science Disease Engineering 52

Codon

OCTOBER 27, 2024

Today, scientists would halt clinical research on drugs with these properties, but back then, many researchers put stock in the “magic bullet” theory proposed by Paul Ehrlich , a German biologist. tuberculosis known as rpoB , which codes for part of its RNA polymerase.

Immune Response 99

Immune Response Doctors Disease Laboratories 99